A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD (MeMAGEN)
A Phase - IIa - IIb, Open Label, Single Center Trial to Study the Safety, Tolerability and Efficacy of Memantine Teva® as Supportive Long-term Treatment in Symptomatic Sickle Cell Disease
Sponsor: HaEmek Medical Center, Israel
This PHASE2 trial investigates Sickle Cell Disease and is currently ongoing. HaEmek Medical Center, Israel leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- HaEmek Medical Center, Israel
For direct contact, visit the study record on ClinicalTrials.gov .